A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus
The human respiratory syncytial virus (hRSV) constitutes a major health burden, causing millions of hospitalizations in children under five years old worldwide due to acute lower respiratory tract infections. Despite decades of research, licensed vaccines to prevent hRSV are not available. Developme...
Main Authors: | Fabián E. Díaz, Mariana Guerra-Maupome, Paiton O. McDonald, Daniela Rivera-Pérez, Alexis M. Kalergis, Jodi L. McGill |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.664212/full |
Similar Items
-
Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults
by: Gaspar A. Pacheco, et al.
Published: (2023-07-01) -
A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus
by: Emma Rey-Jurado, et al.
Published: (2017-09-01) -
New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV
by: Nicolás M. S. Gálvez, et al.
Published: (2017-08-01) -
Auxotrophic <i>Mycobacterium bovis</i> BCG: Updates and Perspectives
by: Odir Antônio Dellagostin, et al.
Published: (2022-05-01) -
Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice
by: Monalisa Martins Trentini, et al.
Published: (2022-08-01)